US FDA approves Regeneron's rare bone disorder drug

The ​U.S. FDA on Wednesday approved Regeneron's experimental drug for a ‌rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。